Nimoutuzumab Injection

Nimoutuzumab Injection
Product Description

Our flagship product, Nimotuzumab, is a humanized anti‑EGFR monoclonal antibody. Since its launch in China in 2008, it has been approved for the treatment of nasopharyngeal carcinoma, pancreatic cancer, and head and neck tumors, demonstrating robust clinical efficacy and a favorable safety profile. Annual sales of Nimotuzumab have reached nearly RMB 1.5 billion (approximately USD 200 million). 

Read more Show less

Biotech Pharmaceutical Co., Ltd.

  • Country/Region:
    China
  • Founded:
    2000
  • On CPHI since:
    2026
  • Certificates:
    1
  • Employees:
    1000 - 4999
Company types
Pharmaceutical company
Primary activities
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile
Categories
more categories Show less
Specifications
  • Details
    50mg(1oml)/vial
  • Selling Points
    Experienced Technicians; Immune Health;
  • Safe and effective – favorable safety profile with proven clinical efficacy.

    • The only biologic drug approved in China for pancreatic cancer – a unique position in the market.

    Multiple approved indications – currently approved for head and neck cancer, pancreatic cancer, and nasopharyngeal carcinoma, with gastric and cervical cancer indications in Phase III clinical trials.

    Strong market performance – exceeded RMB 1.5 billion in annual sales in China last year.

  • Supplied from
    China
  • Measured In
    piece
    • More specifications Fewer specifications
    Sales Markets
    Show more Show less

    Biotech Pharmaceutical Co., Ltd.

    • Country/Region:
      China
    • Founded:
      2000
    • On CPHI since:
      2026
    • Certificates:
      1
    • Employees:
      1000 - 4999
    Company types
    Pharmaceutical company
    Primary activities
    Pharmaceutical Company (generic finished products)
    Pharmaceutical Company (innovator finished products)
    View company profile

    More Products from Biotech Pharmaceutical Co., Ltd. (3)

    • Apalutamide /ˌeɪpəˈluːtəmaɪd/ Tablets / 阿帕他胺片

      Product Apalutamide /ˌeɪpəˈluːtəmaɪd/ Tablets / 阿帕他胺片

      • Large and fast-growing market – global sales reached 3.574 billion USD, with growth exceeding that of enzalutamide.

      Only the originator (Janssen) is available in China; generic entry is expected to achieve rapid volume uptake.

      Expanding patient pool – prostate cancer incidence is ...
    • Axitinib Tablets / 阿昔替尼片

      Product Axitinib Tablets / 阿昔替尼片

      • Largest-selling drug in the global renal cancer market – global sales reached 978 million USD in 2024, with a 5-year CAGR of 12.7%.

      The only approved first-line targeted-immunotherapy combination in China (with toripalimab), listed as Category IA recommendation in 2024 CSCO guidelines.
      ...
    • Ebidetide Injection (JY09) / 益百得肽注射液

      Product Ebidetide Injection (JY09) / 益百得肽注射液

      1.Has a half-life of up to 240 hours and is the first bi-weekly GLP-1 receptor agonist globally to enter Phase III, significantly improving patient compliance.2.Precisely regulates insulin secretion only when blood glucose is elevated, resulting in an extremely low risk of hypoglycemia.3.Incidence of ...